🇺🇸 FDA
Pipeline program

GTX-101

GTX-101-004

Phase 1 small_molecule active

Quick answer

GTX-101 for Postherpetic Neuralgia is a Phase 1 program (small_molecule) at Grace Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Grace Therapeutics
Indication
Postherpetic Neuralgia
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials